{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:36:31Z","timestamp":1778963791145,"version":"3.51.4"},"reference-count":110,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Although discovered 40 years ago, Helicobacter pylori infection is still raising diagnostic and therapeutic problems today. The infection is currently managed based on statements in several guidelines, but implementing them in practice is a long process. Increasing antibiotic resistance and weak compliance of the patients limit the efficacy of eradication regimens, leaving much room for improvement. Third-generation proton pump inhibitors have added little to the results of the first two generations. Potassium-competitive acid blockers have a stronger and longer inhibitory action of acid secretion, increasing the intragastric pH. They obtained superior results in eradication when compared to proton pump inhibitors. Instead of innovative antibiotics, derivatives of existing antimicrobials were developed; some new fluoroquinolones and nitazoxanide seem promising in practice, but they are not recommended by the guidelines. Carbonic anhydrase inhibitors have both anti-secretory and bactericidal effects, and some researchers are expecting their revival in the treatment of infection. Capsules containing components of the eradication regimens have obtained excellent results, but are of limited availability. Probiotics, if containing bacteria with anti-Helicobacter pylori activity, may be useful, increasing the rates of eradication and lowering the prevalence and severity of the side effects.<\/jats:p>","DOI":"10.3390\/antibiotics12060946","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T08:14:28Z","timestamp":1684829668000},"page":"946","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Newer, Older, and Alternative Agents for the Eradication of Helicobacter pylori Infection: A Narrative Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2926-1637","authenticated-orcid":false,"given":"Gy\u00f6rgy Mikl\u00f3s","family":"Buz\u00e1s","sequence":"first","affiliation":[{"name":"Ferencv\u00e1ros Health Centre, Gastroenterology, Mester utca 45, 1095 Budapest, Hungary"},{"name":"Medoc Health Centre, Gastroenterology, Lehel \u00fat 8, 1137 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Birinyi","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University, Szentkir\u00e1lyi utca 46, 1086 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"ref_1","first-page":"1022303","article-title":"Targeting Helicobacter pylori for antibacterial drug discovery with novel therapeutics","volume":"70","author":"Viota","year":"2022","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1007\/s00253-020-10945-w","article-title":"Helicobacter pylori treatment in the post-antibiotics era\u2014Searching for new drug targets","volume":"104","author":"Wojtys","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cgh.2021.03.026","article-title":"Primer for development of guidelines for Helicobacter pylori therapy using antimicrobial stewardship","volume":"20","author":"Graham","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto Consensus for the treatment of Helicobacter pylori in adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG Guideline: Treatment of Helicobacter pylori infection","volume":"112","author":"Chey","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection: The Maastricht V\/Florence consensus report","volume":"66","author":"Malfertheiner","year":"2017","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.gastro.2019.04.011","article-title":"Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics","volume":"157","author":"Fallone","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: The Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","article-title":"Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: A network meta-analysis","volume":"181","author":"Rokkas","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/gutjnl-2021-326170","article-title":"Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy","volume":"71","author":"Graham","year":"2022","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/gutjnl-2020-321372","article-title":"European Registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients","volume":"70","author":"Nyssen","year":"2021","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/MCG.0000000000001482","article-title":"Room for improvement in the treatment of Helicobacter pylori infection: Lessons from the European Registry on H. pylori management (Hp-EuReg)","volume":"56","author":"Nyssen","year":"2022","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1111\/bcp.14076","article-title":"Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control","volume":"85","author":"Wang","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"771876","DOI":"10.3389\/fphar.2022.771876","article-title":"Comparison of the dual therapy of ilaprazole-amoxicillin and the bismuth quadruple therapy of ilaprazole-amoxicillin-furazolidone-bismuth glycyrrhizinate for eradication of Helicobacter pylori","volume":"13","author":"Niu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Chi, J., Xu, C., Liu, X., Wu, H., Xie, X., Liu, P., Li, H., Zhang, G., Xu, M., and Li, C. (2022). A comparison of doxycyclin and amoxicillin containing quadruple eradication therapy for treating Helicobacter pylori-infected duodenal ulcers: A multicenter, opened, randomized controlled trial in China. Pathogens, 11.","DOI":"10.3390\/pathogens11121549"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1365-2036.2009.03984.x","article-title":"Review article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitory therapy","volume":"29","author":"Metz","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/hel.12126","article-title":"High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infection","volume":"19","author":"Atumi","year":"2014","journal-title":"Helicobacter"},{"key":"ref_18","first-page":"e2696","article-title":"A pilot randomized controlled study of dexlansoprazole MR-based triple therapy for Helicobacter pylori infection","volume":"954","author":"Wu","year":"2016","journal-title":"Medicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.7314\/APJCP.2015.16.10.4353","article-title":"High efficacy of levofloxacin-based quadruple therapy as a first line treatment for Helicobacter pylori eradication in Thailand","volume":"16","author":"Prapitpaiboon","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1756284819870960","DOI":"10.1177\/1756284819870960","article-title":"Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections","volume":"12","author":"Kuo","year":"2019","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2147\/IDR.S213998","article-title":"A comparison between dexlansoprazole modified release-based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: A prospective randomized trial","volume":"12","author":"Tai","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2036.2009.04219.x","article-title":"The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects","volume":"31","author":"Hunt","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers\u2014Are they the next generation of proton pump inhibitors","volume":"9","author":"Rawla","year":"2018","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5056\/jnm18029","article-title":"Potent potassium-competitive acid blockers: A new era for the treatment of acid-related diseases","volume":"24","author":"Oshima","year":"2018","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1248\/bpb.18.1053","article-title":"Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor","volume":"18","author":"Tsuchiya","year":"1995","journal-title":"Biol. Pharm. Bull."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10620-016-4439-0","article-title":"Effect of vonoprazan, a potassium-competitive acid blocker, on the 13C-urea breath test in Helicobacter pylori-positive patients","volume":"62","author":"Takimoto","year":"2017","journal-title":"Dig. Di. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e12438","DOI":"10.1111\/hel.12438","article-title":"Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?","volume":"22","author":"Dong","year":"2017","journal-title":"Helicobacter"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: The efficacy of vonoprazan triple therapy on Helicobacter pylori eradication","volume":"46","author":"Jung","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e12495","DOI":"10.1111\/hel.12495","article-title":"Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori","volume":"23","author":"Li","year":"2018","journal-title":"Helicobacter"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100058","DOI":"10.1016\/j.clinsp.2022.100058","article-title":"Efficacy and safety of potassium-compatitive acid blockers versus proton pump inhibitors as Helicobacter pylori eradication therapy: A meta-analysis of randomized clinical trials","volume":"77","author":"Zhang","year":"2022","journal-title":"Clinics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000504939","article-title":"Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: Systematic review and meta-analysis","volume":"102","author":"Shinozaki","year":"2021","journal-title":"Digestion"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1053\/j.gastro.2022.05.055","article-title":"Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: Randomized clinical trial","volume":"163","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","article-title":"A report card to grade Helicobacter pylori therapy","volume":"12","author":"Graham","year":"2007","journal-title":"Helicobacter"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.5009\/gnl220055","article-title":"Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: A randomized, double- blind, phase III clinical trial","volume":"16","author":"Choi","year":"2022","journal-title":"Gut Liver"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Park, C.H., Song, M.J., Jung, B.W., Park, J.H., and Jung, Y.S. (2022). Comparative efficacy of 14- days tegoprazan-based triple vs. 10-days tegoprazan-based concomitant therapy for Helicobacter pylori eradication. J. Pers. Med., 12.","DOI":"10.3390\/jpm12111918"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Boyanova, L., Hadzhisky, P., Gergova, R., and Markovska, R. (2023). Evolution of Helicobacter pylori resistance to antibiotics: A topics of increasing concern. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020332"},{"key":"ref_37","unstructured":"World Health Organization (2017). WHO Publishes List of Bacteria for Which New Antibiotics are Urgently Needed, World Health Organization."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e12686","DOI":"10.1111\/hel.12686","article-title":"Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)","volume":"25","author":"Nyssen","year":"2020","journal-title":"Helicobacter"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s101560050036","article-title":"Beta-lactamase inhibitors have antibacterial activities against Helicobacter pylori","volume":"4","author":"Horii","year":"1999","journal-title":"J. Infect. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.0954-6820.2003.01239.x","article-title":"Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate","volume":"255","author":"Ojetti","year":"2004","journal-title":"J. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Song, Z., Fu, W., and Zhou, L. (2019). Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin. BMC Gastroenterol., 19.","DOI":"10.1186\/s12876-019-1056-3"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/bph.13936","article-title":"The macrolide antibiotic resistance","volume":"174","author":"Dinos","year":"2017","journal-title":"Brit. J. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.44.9.2518-2520.2000","article-title":"In vitro activities of a new ketolide, ABT-773, alone and in combination with amoxicillin, metronidazole, or tetracycline against Helicobacter pylori","volume":"44","author":"Pendland","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.diagmicrobio.2009.10.013","article-title":"CEM-101, a novel fluoroketolide: Antimicrobial activity against diverse collection of Gram-positive and Gram-negative bacteria","volume":"66","author":"Putnam","year":"2010","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"ref_45","first-page":"1407","article-title":"Ofloxacin in the therapy of Campylobacter pylori positive duodenal ulcer. A prospective randomized trial","volume":"112","author":"Kasper","year":"1987","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/AAC.00049-09","article-title":"Sitafloxacin and garenoxacin may overcome the antibiotics resistance of Helicobacter pylori with gyr A mutation","volume":"53","author":"Suzuki","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Nishizawa, T., Munkjargal, M., Ebinuma, H., Toyoshima, O., and Suzuki, H. (2021). Sitafloxacin for third-line Helicobacter pylori eradication: A systematic reviews. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122722"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3164\/jcbn.08-220R","article-title":"Quinolone-based third-line therapy for Helicobacter pylori","volume":"44","author":"Nishizawa","year":"2009","journal-title":"J. Clin. Biochem. Nutr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1365-2036.2006.03072.x","article-title":"Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection","volume":"24","author":"Graham","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1128\/AAC.01467-15","article-title":"High efficacy of finafloxacin on Helicobacter pylori isolates at pH 5.0 compared with that of other fluoroquinolones","volume":"59","author":"Lee","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"114890","DOI":"10.1016\/j.diagmicrobio.2019.114980","article-title":"Delafloxacin against Helicobacter pylori, a potential option for improving eradication success?","volume":"96","author":"Boyanova","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Lai, C.-C., Chen, K.-H., Chemn, C.H., and Wang, C.-Y. (2021). The association between the risk of aortic aneurysm\/aortic dissection and the use of fluoroquinolones: A systematic review and meta-analysis. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060697"},{"key":"ref_53","first-page":"233","article-title":"Aneurysm and Helicobacter pylori relationship: The seropositivity of CagA, VacA and other antigens of Helicobacter pylori in abdominal and ascending aortic aneurysm","volume":"33","author":"Ziver","year":"2010","journal-title":"New Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Tytgat, G.N.J. (1990). Helicobacter pylori\u2014Causal Agent in Peptic Ulcer Disease, Blackwell Scientific.","DOI":"10.1111\/j.1440-1746.1991.tb01453.x"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"The European Helicobacter Pylori Study Group (1997). Current European concepts in the management of Helicobacter pylori infection, The Maastricht Consensus Report. Gut, 41, 8\u201313.","DOI":"10.1136\/gut.41.1.8"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Sun, Y., Zhu, M., Yue, L., and Hu, W. (2022). Multiple bismuth quadruple therapy containing tetracylines combined with other antibiotics and Helicobacter pylori eradication therapy. J. Clin. Med., 11.","DOI":"10.3390\/jcm11237040"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e12830","DOI":"10.1111\/hel.12830","article-title":"Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections\u2014Exploratory study","volume":"16","author":"Gunaratne","year":"2021","journal-title":"Helicobacter"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000443683","article-title":"Doxycycline in eradication therapy of Helicobacter pylori\u2014A systematic review and meta-analysis","volume":"93","author":"Niv","year":"2016","journal-title":"Digestion"},{"key":"ref_59","first-page":"3237","article-title":"Minocycline: Far beyond an antibiotic","volume":"169","author":"Zarzuelo","year":"2013","journal-title":"Brit. J. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e12839","DOI":"10.1111\/hel.12839","article-title":"Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis","volume":"26","author":"Zhao","year":"2021","journal-title":"Helicobacter"},{"key":"ref_61","first-page":"1054","article-title":"Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8 year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg)","volume":"72","author":"Nyssen","year":"2022","journal-title":"Gut"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Rusu, A., and Buta, E.L. (2021). The development of third-generation tetracycline antibiotics and new perspectives. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122085"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Heidrich, C., Mitova, S., Schedlbauer, A., Connell, S.R., Fucini, P., Steenbeergen, J.N., and Berens, C. (2016). The novel aminomethylcycline omadacycline has high specificity for the primary tetracycline bindigs site on the bacterial ribosome. Antibiotics, 5.","DOI":"10.3390\/antibiotics5040032"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1128\/AAC.42.11.2836","article-title":"Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole","volume":"42","author":"Occhialini","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"260","DOI":"10.14740\/gr1342","article-title":"Safety and efficacy of nitazoxanide-based regimen for the eradication of Helicobacter-pylori infection: A systematic review and meta-analysis","volume":"13","author":"Iqbal","year":"2020","journal-title":"Gastroenterol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e00073-22","DOI":"10.1128\/aac.00073-22","article-title":"Linolenic acid-metronidazole: A compound relieving drug resistance and inhibiting Helicobacter pylori","volume":"56","author":"Dai","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1021\/acs.jmedchem.1c02045","article-title":"Design, synthesis and characterization of TNP-21098, a dual targeted rifamycin-nitroimidazole conjugate with potent activity against microaerophilic and anaerobic bacterial pathogens","volume":"65","author":"Ma","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF00144743","article-title":"Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents","volume":"4","author":"Glupczynski","year":"1988","journal-title":"Eur. J. Epidemiol."},{"key":"ref_69","first-page":"1048","article-title":"Double-blind short-term trial of furazolidone in peptic ulcer","volume":"1","author":"Zheng","year":"1985","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/j.1440-1746.2007.05082.x","article-title":"Nitrofuran-based regimens for the eradication of Helicobacter pylori infection","volume":"22","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/1319-3767.91729","article-title":"Furazolidone-based therapies for Helicobacter pylori infection: A pooled-data analysis","volume":"18","author":"Zullo","year":"2012","journal-title":"Saud. J. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e12468","DOI":"10.1111\/hel.12468","article-title":"Furazolidone treatment for Helicobacter pylori infection: A systematic review and meta-analysis","volume":"23","author":"Zhuge","year":"2018","journal-title":"Helicobacter"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e03735","DOI":"10.1136\/bmjopen-2020-037375","article-title":"Safety of furazolidon-containing regimen in Helicobacter pylori infection: A systematic review and meta-analysis","volume":"10","author":"Ji","year":"2020","journal-title":"BMJ Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/A:1006333608012","article-title":"Pharmacological, therapeutic and toxicological properties of furazolidone. Some recent research","volume":"23","author":"Ali","year":"1999","journal-title":"Vet. Res. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1007\/s10620-017-4628-5","article-title":"Furazolidone, an underutilized drug for H. pylori eradication: Lessons from Iran","volume":"62","author":"Mohammadi","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2036.2001.00945.x","article-title":"El-Zimaity HMT, Kwon DH, Osato MS. Nitrofurantoin quadruple therapy for Helicobacter pylori infection: Effect of metronidazole resistance","volume":"15","author":"Graham","year":"2001","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_77","first-page":"12","article-title":"Second-line and third-line trial for Helicobacter pylori infection in patients with duodenal ulcers: A prospective, crossover, controlled study","volume":"65","year":"2004","journal-title":"Curr. Ther. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/00365521.2017.1303844","article-title":"Helicobacter pylori eradication in the Swedish population","volume":"52","author":"Doorakkers","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1749-6632.1984.tb12392.x","article-title":"Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors","volume":"429","year":"1984","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_80","first-page":"97","article-title":"Treatment of duodenal ulcers with ethoxzolamide, an inhibitor of gastric carbonic anhydrase","volume":"24","year":"1986","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3109\/14756366.2015.1051042","article-title":"The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers. In memorian Ioan Pu\u015fca\u015f (1932\u20132015)","volume":"31","author":"Supuran","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13099-020-00358-5","article-title":"Antibacterial activity of ethoxzolamide against Helicobacter pylori strains SS and 26695","volume":"12","author":"Rahman","year":"2020","journal-title":"Gut Pathog."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1080\/14756366.2019.1663416","article-title":"Anti-Helicobacter pylori activity of ethoxzolamide","volume":"34","author":"Modak","year":"2019","journal-title":"J. Enzym Inhib. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"629163","DOI":"10.3389\/fmicb.2021.629163","article-title":"Carbonic anhydrases: New perspectives on protein functional role and inhibition in Helicobacter pylori","volume":"12","author":"Campestre","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543776.2020.1811853","article-title":"Antibacterial carbonic anhydrase inhibitors: An update on the recent literature","volume":"30","author":"Supuran","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MD.0000000000027923","article-title":"The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication. A multicenter, randomized, controlled clinical trial","volume":"100","author":"Cao","year":"2021","journal-title":"Medicine"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Pylera Study Group: Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole and tetracycline given with omeprazole versus clarithromycin-based triple therapy: A randomised, open-label, non-inferiority phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e12570","DOI":"10.1111\/hel.12570","article-title":"Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori","volume":"24","author":"Nyssen","year":"2019","journal-title":"Helicobacter"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000350719","article-title":"Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection","volume":"88","author":"Venerito","year":"2013","journal-title":"Digestion"},{"key":"ref_90","first-page":"27","article-title":"The optimum location of bismuth in the treatment of Helicobacter pylori infection","volume":"5","author":"Birinyi","year":"2016","journal-title":"Central Eur. J. Gastroent. Hepatol."},{"key":"ref_91","first-page":"144","article-title":"The efficacy of bismuth-based quadruple therapy in the second-line treatment of Helicobacter pylori infection","volume":"4","author":"Birinyi","year":"2018","journal-title":"Central Eur. J. Gastroenterol. Hepatol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Dore, M.P., Saba, F., Zanni, L., Rocca, A., Piroddu, J., Gutierrez, G., and Pes, G.M. (2023). A simplified low-dose 10 day quadruple therapy with galenic formulation of bismuth salicylate is highly effective for Helicobacter pylori eradication. J. Clin. Med., 12.","DOI":"10.3390\/jcm12020681"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jsps.2014.02.009","article-title":"Design and evaluation of gastroretentive levofloxacin floating mini-tablets-in-capsule system for eradication of Helicobacter pylori","volume":"22","author":"Kassem","year":"2014","journal-title":"Saud. Pharmaceutical. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"962354","DOI":"10.3389\/fmicb.2022.962354","article-title":"Revealing the novel effect of Jinghua Weikang capsule against the antibiotics resistance of Helicobacter pylori","volume":"13","author":"Jia","year":"2022","journal-title":"Front. Microbiol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Li, Z., Ren, B., Tan, H., Liu, S., Wang, W., Pang, Y., Lin, J., and Zeng, C. (2016). Capsule designs for blue light therapy against Helicobacter pylori. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147531"},{"key":"ref_96","unstructured":"Watson, R.R., and Preedy, V.R. (2016). Probiotics, Prebiotics and Synbiotics, Academic Press-Elsevier."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3748\/wjg.v24.i1.139","article-title":"Probiotics monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis","volume":"24","author":"Losurdo","year":"2018","journal-title":"World J. Gastroentrerol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"J4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised and non-randomised studies of healthcare interventions or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"ref_99","first-page":"6","article-title":"Quality assessment of meta-analyses: Probiotics and eradication of Helicobacter pylori infection","volume":"30","year":"2020","journal-title":"Helicobacter"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e15180","DOI":"10.1097\/MD.0000000000015180","article-title":"Efficacy and safety of probiotics in eradicating Helicobacter pylori. A network meta-analysis","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Viazis, N., Argyriou, K., Kotzampassi, K., Christodoulu, D.K., Apostolopoulos, P., Georgopoulos, S.D., Liatsos, C.X., Giouleme, O., Koustenis, K., and Veretanos, C. (2022). A four- probiotics regimen combined with standard Helicobacter pylori-eradication treatment reduces side effects and increases eradication rates. Nutrients, 14.","DOI":"10.3390\/nu14030632"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1042070","DOI":"10.3389\/fcimb.2022.1042070","article-title":"Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics","volume":"12","author":"Liang","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/gutjnl-2021-325630","article-title":"Chinese consensus report on family-based Helicobacter pylori infection control and maganement (2021 edition)","volume":"71","author":"Ding","year":"2022","journal-title":"Gut"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e12889","DOI":"10.1111\/hel.12889","article-title":"Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study","volume":"27","author":"Song","year":"2022","journal-title":"Helicobacter"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5009\/gnl20288","article-title":"Evidence-based guidelines for the treatment of Helicobacter pylori infection in Korea 2020","volume":"15","author":"Jung","year":"2021","journal-title":"Gut Liver"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e12597","DOI":"10.1111\/hel.12597","article-title":"Guidelines for the management of Helicobacter pylori infection in Japan. 2016 revised edition","volume":"24","author":"Kato","year":"2019","journal-title":"Helicobacter"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.12998\/wjcc.v10.i19.6349","article-title":"Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan and South Korea","volume":"101","author":"Cho","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1007\/s12664-021-01186-4","article-title":"Management of Helicobacter pylori infection: The Bhubaneswar Consensus Reeport of the Indian Society of Gastroenterology","volume":"40","author":"Singh","year":"2021","journal-title":"Indian J. Gastroenterol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1590\/s0004-2803.201800000-20","article-title":"IVth Brazilian consensus conference on Helicobacter pylori infection","volume":"55","author":"Coelho","year":"2018","journal-title":"Arq. Gastroenterol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"102331","DOI":"10.1016\/j.bjid.2022.102331","article-title":"Treatment regimens used in the management of Helicobacter pylori in Colombia","volume":"26","year":"2022","journal-title":"Braz. J. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/946\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:40:22Z","timestamp":1760125222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/6\/946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":110,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["antibiotics12060946"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12060946","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]}}}